OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• OptimizeRx Corp. has received a consensus rating of "Moderate Buy" from twelve brokerages, with one analyst issuing a "strong buy" rating and the average 12-month price target set at $11.81.
• Institutional investors have heavily invested in OptimizeRx, with notable increases in holdings, including a 600% increase by Nisa Investment Advisors LLC during the second quarter.
• OptimizeRx's stock performance shows significant volatility with a 52-week low of $3.78 and a high of $19.25, highlighting its market potential.

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve brokerages that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $11.8125.

A number of analysts recently commented on the stock. Zacks Research upgraded shares of OptimizeRx from a "hold" rating to a "strong-buy" rating in a report on Friday, September 5th. Stifel Nicolaus boosted their target price on shares of OptimizeRx from $16.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Roth Capital reiterated a "buy" rating on shares of OptimizeRx in a report on Friday, August 8th. JMP Securities boosted their target price on shares of OptimizeRx from $14.00 to $20.00 and gave the stock a "market outperform" rating in a report on Monday, August 11th. Finally, Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd.

Insider Activity

In other news, Director Patrick D. Spangler sold 11,120 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $17.49, for a total transaction of $194,488.80. Following the sale, the director owned 44,215 shares in the company, valued at $773,320.35. The trade was a 20.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OptimizeRx

Large investors have recently made changes to their positions in the company. American Century Companies Inc. grew its position in OptimizeRx by 9.6% during the first quarter. American Century Companies Inc. now owns 15,783 shares of the company's stock valued at $137,000 after purchasing an additional 1,387 shares in the last quarter. Nisa Investment Advisors LLC grew its position in OptimizeRx by 600.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company's stock valued at $29,000 after purchasing an additional 1,818 shares in the last quarter. Bank of New York Mellon Corp grew its position in OptimizeRx by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 89,538 shares of the company's stock valued at $775,000 after purchasing an additional 1,826 shares in the last quarter. BNP Paribas Financial Markets grew its position in OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company's stock valued at $55,000 after purchasing an additional 2,215 shares in the last quarter. Finally, Rhumbline Advisers grew its position in OptimizeRx by 10.5% during the first quarter. Rhumbline Advisers now owns 27,785 shares of the company's stock valued at $241,000 after purchasing an additional 2,636 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company's stock.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX traded up $0.28 during trading on Wednesday, reaching $17.61. The company had a trading volume of 114,953 shares, compared to its average volume of 380,066. The firm's fifty day moving average is $15.36 and its 200 day moving average is $11.92. The firm has a market capitalization of $327.04 million, a PE ratio of -32.68 and a beta of 1.20. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $19.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.57 and a current ratio of 2.57.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.